TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04830995

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: moderate restricted diet (1800-2000 kcal/day) for four weeks
Description: high intensity interval training 3 sessions for four weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: moderate restricted diet (1800-2000 kcal/day) for four weeks
Description: high intensity interval training 3 sessions for four weeks
Study: NCT03393013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Subcutaneous Injection of KZR-616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Subcutaneous Injection of KZR-616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Subcutaneous Injection of KZR-616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KZR-616
Description: Subcutaneous Injection of KZR-616
Study: NCT00872170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg
Study: NCT02461485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented milk product containing Probiotics
Description: 2 pots/day during 28 days
Study: NCT00948909

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Experimental intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Experimental intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Active comparator intervention
Study: NCT02473237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
Study: NCT04673825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient initiated care + telemonitoring
Description: See arm/group descriptions.
Study: NCT04091763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Injectable Foam
Description: Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Description: Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery.
Study: NCT04898816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure of wound using n- butyl 2-octyl cyanoacrylate tissue adhesive
Description: Application of cyanoacrylate tissue adhesives over the surgical wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of wound using braided silk suture
Description: suturing the surgical wound using braided black silk
Study: NCT04550260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Durvalumab matching placebo for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + fluorouracil
Description: cisplatin + fluorouracil, as per Standard of Care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin + fluorouracil
Description: cisplatin + fluorouracil, as per Standard of Care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin + capecitabine
Description: cisplatin + capecitabine, as per Standard of Care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin + capecitabine
Description: cisplatin + capecitabine, as per Standard of Care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 50-64Gy in total

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation
Description: 50-64Gy in total
Study: NCT03704974

Intervention type: BEHAVIORAL
Intervention: Video-Based Parent Training Program
Description: An18-20 week evidence-based social cognitive theory-based parenting program where parents see brief video vignettes of effective and less effective parenting and develop concepts to modify their child's behavior.
Study: NCT01627340

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B vaccine
Description: 3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B vaccine
Description: 3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study: NCT03513211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Description: 150mg PO BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Description: 150mg PO BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Escalating doses in Rolling 6 Phase I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Escalating doses in Rolling 6 Phase I
Study: NCT01272011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Intermittent Hypoxia
Description: Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
Study: NCT04423939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: The ACT sessions will be tailored to the clinical challenges of HCT. Sessions are with a mental health professional and are 45-60 minutes in duration and include both the participant and caregiver.
Study: NCT01272011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
Study: NCT03416387

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D PRINTING
Description: A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
Study: NCT03320083

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational care derived from POSSUMS
Description: Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
Study: NCT01333787

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Fiber Mixture
Description: During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Fiber Mixture
Description: During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg.
Study: NCT05394129

Intervention type: DIAGNOSTIC_TEST
Intervention: SurePath™
Description: In the liquid-based cytology, a fine-needle aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
Study: NCT03105765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
Study: NCT02461485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented Milk Product containing Probiotics + Fibers C
Description: 2 pots/day during 28 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented Milk Product containing Probiotics + Fibers W
Description: 2 pots/day during 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non fermented Milk Product
Description: 2 pots/day during 28 days
Study: NCT02016417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A combination of Gemcitabine and cisplatin
Description: The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
Study: NCT00117442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Chemotherapy
Study: NCT02016417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A combination of Docetaxel, cisplatin and 5-Fluorouracil
Description: The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
Study: NCT03691623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938 Dose 1
Description: Oral suspension for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938 Dose 2
Description: Oral suspension for 5 days
Study: NCT00117442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Chemotherapy
Study: NCT04311073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: IV Tranexamic acid in 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
Study: NCT03691623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938 Dose 3
Description: Oral suspension for 5 days
Study: NCT04311073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV normal saline 50 ml will be given 15 minutes prior to initial surgical incision in the placebo group.
Study: NCT03691623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938 Dose 4
Description: Oral suspension for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension for 5 days
Study: NCT04187222

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical debridements
Description: Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical debridements
Description: Prior to the beginning of the intervention, all patients received oral hygiene instruction. Mechanical debridements were performed with titanium curette and polishing using a rubber bowl and polishing paste.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis
Description: Capsules containing Bifidobacterium animalis subsp. lactis were chubby and subsequently ingested twice a day for 12 weeks.
Study: NCT01740622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury Prevention Measures
Description: The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
Study: NCT02998008

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: high intensity interval training

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: high intensity interval training
Study: NCT01809262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 5 mcg
Description: solution for inhalation
Study: NCT00117442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Growth factor for mobilization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Growth factor for mobilization
Study: NCT01809262

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: single dose of placebo
Description: solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 40 mcg
Description: solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 20 mcg
Description: solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 2 mcg
Description: solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of 10 mcg
Description: solution for inhalation
Study: NCT02773758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride Dentifrice
Description: Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium monofluorophosphate Dentifrice
Description: Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
Study: NCT05159232

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hospital stay
Description: hospital stay in in inguinal hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hospital stay
Description: hospital stay in in inguinal hernia repair
Study: NCT00117442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Growth factor for mobilization
Study: NCT00637273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2.0mg, once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: oral tablet, 100mg, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: oral tablet, 45mg, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo tablet
Description: oral tablet, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo once weekly
Description: subcutaneous injection, once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo once weekly
Description: subcutaneous injection, once a week
Study: NCT01279135

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiation
Description: Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy based IGRT
Description: Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
Study: NCT01798706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidiabetic background therapy
Description: Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidiabetic background therapy
Description: Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide \>10 mg, gliclazide \>160 mg), meglitinides (except repaglinide \>6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
Study: NCT03797950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Reminder (Group A)
Description: Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentive (Group B)
Description: Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
Study: NCT00824486

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury prevention education (TIPP)
Description: using TIPP materials

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injury prevention education (safe home)
Description: using safe home model
Study: NCT03637842

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Lorcaserin XR 20mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT03736083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freestyle Libre Blood Glucose Monitor
Description: The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis